Tecartus
Drug
Kite Pharma, Inc.
Total Payments
$15.7M
Transactions
2,005
Doctors
229
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2.8M | 262 | 12 |
| 2023 | $3.0M | 412 | 68 |
| 2022 | $3.2M | 400 | 90 |
| 2021 | $2.4M | 487 | 105 |
| 2020 | $2.7M | 258 | 80 |
| 2018 | $1.5M | 186 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $14.4M | 1,197 | 91.9% |
| Consulting Fee | $1.1M | 414 | 6.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $152,105 | 76 | 1.0% |
| Travel and Lodging | $38,810 | 113 | 0.2% |
| Food and Beverage | $8,167 | 200 | 0.1% |
| Education | $99.95 | 5 | 0.0% |
Payments by Type
Research
$14.4M
1,197 transactions
General
$1.3M
808 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA 2) | Kite Pharma, Inc. | $10.6M | 0 |
| A Multicenter, Open-label Expanded Access Study of KTE-X19 in Subjects with B-Cell Malignancies | Kite Pharma, Inc. | $2.6M | 0 |
| Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel | Kite Pharma, Inc. | $911,217 | 0 |
| A Multicenter, Open-label Expanded Access Study of KTE-X19 in Subjects with B-Cell Malignancies | Gilead Sciences, Inc. | $295,946 | 0 |
Top Doctors Receiving Payments for Tecartus
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Nashville, TN | $14.4M | 1,197 |
| , MD | Internal Medicine | New York, NY | $46,264 | 23 |
| , M.D | Hematology & Oncology | Houston, TX | $44,361 | 28 |
| , M.D | Internal Medicine | Seattle, WA | $36,026 | 14 |
| , M.D | Hematology & Oncology | Houston, TX | $29,709 | 21 |
| , MD | Hematology | Buffalo, NY | $27,705 | 20 |
| , MD, PHD | Student in an Organized Health Care Education/Training Program | Rochester, MN | $27,084 | 24 |
| , M.D | Medical Oncology | Durham, NC | $23,080 | 10 |
| , MD | Hematology & Oncology | Philadelphia, PA | $22,420 | 10 |
| , M.D.,PH.D | Hematology & Oncology | Boston, MA | $20,080 | 13 |
| , MD | Internal Medicine | Houston, TX | $19,732 | 11 |
| , M.D | Internal Medicine | Little Rock, AR | $18,503 | 22 |
| , MD, PHD | Internal Medicine | San Francisco, CA | $18,424 | 14 |
| , MD, MPH | Hospitalist | Nashville, TN | $17,332 | 11 |
| Peter Riedell | Hematology & Oncology | Chicago, IL | $16,315 | 13 |
| , MD, PHD | Internal Medicine | Baltimore, MD | $15,950 | 6 |
| , D.O | Internal Medicine | Omaha, NE | $14,941 | 7 |
| Michael Bishop | Hematology & Oncology | Chicago, IL | $14,529 | 8 |
| , M.D | Hematology & Oncology | Dallas, TX | $13,520 | 7 |
| , M.D | Internal Medicine | Palo Alto, CA | $12,921 | 8 |
| , M.D., PH.D | Hematology & Oncology | Cleveland, OH | $12,369 | 12 |
| , M.D | Hematology & Oncology | Tampa, FL | $12,239 | 15 |
| , MD | Hematology | Hackensack, NJ | $11,996 | 6 |
| , MD | Hematology | Sioux Falls, SD | $11,867 | 9 |
| , M.D | Hematology | Hackensack, NJ | $11,530 | 4 |
Ad
Manufacturing Companies
- Kite Pharma, Inc. $15.4M
- Gilead Sciences, Inc. $356,095
Product Information
- Type Drug
- Total Payments $15.7M
- Total Doctors 229
- Transactions 2,005
About Tecartus
Tecartus is a drug associated with $15.7M in payments to 229 healthcare providers, recorded across 2,005 transactions in the CMS Open Payments database. The primary manufacturer is Kite Pharma, Inc..
Payment data is available from 2018 to 2024. In 2024, $2.8M was paid across 262 transactions to 12 doctors.
The most common payment nature for Tecartus is "Unspecified" ($14.4M, 91.9% of total).
Tecartus is associated with 4 research studies, including "A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA 2)" ($10.6M).